PD-1 and PD-L1 expression in molecularly selected non-small-cell lung cancer patients
- PMID: 25349974
- PMCID: PMC4453606
- DOI: 10.1038/bjc.2014.555
PD-1 and PD-L1 expression in molecularly selected non-small-cell lung cancer patients
Abstract
Background: Agents targeting programmed death-1 receptor (PD-1) and its ligand (PD-L1) are showing promising results in non-small-cell lung cancer (NSCLC). It is unknown whether PD-1/PD-L1 are differently expressed in oncogene-addicted NSCLC.
Methods: We analysed a cohort of 125 NSCLC patients, including 56 EGFR mutated, 29 KRAS mutated, 10 ALK translocated and 30 EGFR/KRAS/ALK wild type. PD-L1 and PD-1 expression were assessed by immunohistochemistry. All cases with moderate or strong staining (2+/3+) in >5% of tumour cells were considered as positive.
Results: PD-1 positive (+) was significantly associated with current smoking status (P=0.02) and with the presence of KRAS mutations (P=0.006), whereas PD-L1+ was significantly associated to adenocarcinoma histology (P=0.005) and with presence of EGFR mutations (P=0.001). In patients treated with EGFR tyrosine kinase inhibitors (N=95), sensitivity to gefitinib or erlotinib was higher in PD-L1+ vs PD-L1 negative in terms of the response rate (RR: P=0.01) time to progression (TTP: P<0.0001) and survival (OS: P=0.09), with no difference in PD1+ vs PD-1 negative. In the subset of 54 EGFR mutated patients, TTP was significantly longer in PD-L1+ than in PD-L1 negative (P=0.01).
Conclusions: PD-1 and PD-L1 are differentially expressed in oncogene-addicted NSCLC supporting further investigation of specific checkpoint inhibitors in combination with targeted therapies.
Figures
Similar articles
-
[Correlation Study on Expression of PD-1 and PD-L1 in Non-small Cell Lung Cancer and Epidermal Growth Factor Receptor Mutations].Zhongguo Fei Ai Za Zhi. 2021 Sep 20;24(9):623-631. doi: 10.3779/j.issn.1009-3419.2021.102.31. Epub 2021 Aug 30. Zhongguo Fei Ai Za Zhi. 2021. PMID: 34455737 Free PMC article. Chinese.
-
Predictive value of oncogenic driver subtype, programmed death-1 ligand (PD-L1) score, and smoking status on the efficacy of PD-1/PD-L1 inhibitors in patients with oncogene-driven non-small cell lung cancer.Cancer. 2019 Apr 1;125(7):1038-1049. doi: 10.1002/cncr.31871. Epub 2018 Dec 11. Cancer. 2019. PMID: 30548240
-
Efficacy of Immune Checkpoint Inhibitors in KRAS-Mutant Non-Small Cell Lung Cancer (NSCLC).J Thorac Oncol. 2019 Jun;14(6):1095-1101. doi: 10.1016/j.jtho.2019.01.011. Epub 2019 Feb 6. J Thorac Oncol. 2019. PMID: 30738221
-
Targeting the PD-1/PD-L1 Immune Checkpoint in EGFR-Mutated or ALK-Translocated Non-Small-Cell Lung Cancer.Target Oncol. 2017 Oct;12(5):563-569. doi: 10.1007/s11523-017-0510-9. Target Oncol. 2017. PMID: 28624922 Review.
-
Epidermal Growth Factor Receptor (EGFR) Pathway, Yes-Associated Protein (YAP) and the Regulation of Programmed Death-Ligand 1 (PD-L1) in Non-Small Cell Lung Cancer (NSCLC).Int J Mol Sci. 2019 Aug 5;20(15):3821. doi: 10.3390/ijms20153821. Int J Mol Sci. 2019. PMID: 31387256 Free PMC article. Review.
Cited by
-
Effect on Non-Small Cell Lung Cancer after Combination of Driver Gene Mutations and Anti-PD-1/PD-L1 Immunotherapy as Well as Chemotherapy.Iran J Public Health. 2024 Aug;53(8):1754-1768. doi: 10.18502/ijph.v53i8.16280. Iran J Public Health. 2024. PMID: 39415861 Free PMC article.
-
Expression of PD-L1 in breast invasive lobular carcinoma.PLoS One. 2024 Oct 10;19(10):e0309170. doi: 10.1371/journal.pone.0309170. eCollection 2024. PLoS One. 2024. PMID: 39388456 Free PMC article.
-
EGFR-TKIs Combined with Allogeneic CD8+ NKT Cell Immunotherapy to Treat Patients with Advanced EGFR-Mutated Lung Cancer.Technol Cancer Res Treat. 2024 Jan-Dec;23:15330338241273198. doi: 10.1177/15330338241273198. Technol Cancer Res Treat. 2024. PMID: 39166278 Free PMC article. Clinical Trial.
-
Predictive Value of Lymphocyte-to-Neutrophil Ratio and Platelet-to-Neutrophil Ratio on PD-L1 Expression in Lung Cancer.Clin Respir J. 2024 Aug;18(8):e13821. doi: 10.1111/crj.13821. Clin Respir J. 2024. PMID: 39140242 Free PMC article.
-
Optimizing immunofluorescence with high-dynamic-range imaging to enhance PD-L1 expression evaluation for 3D pathology assessment from NSCLC tumor tissue.Sci Rep. 2024 Jul 2;14(1):15176. doi: 10.1038/s41598-024-65187-x. Sci Rep. 2024. PMID: 38956114 Free PMC article.
References
-
- Akbay EA, Koyama S, Carretero J, Altabef A, Tchaicha JH, Christensen CL, Mikse OR, Cherniack AD, Beauchamp EM, Pugh TJ, Wilkerson MD, Fecci PE, Butaney M, Reibel JB, Soucheray M, Cohoon TJ, Janne PA, Meyerson M, Hayes DN, Shapiro GI, Shimamura T, Sholl LM, Rodig SJ, Freeman GJ, Hammerman PS, Dranoff G, Wong KK. Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors. Cancer Discov. 2013;3:1355–1363. - PMC - PubMed
-
- Antonia S, Grosso J, Horak C, Harbison C, Kurland J, Inzunza D, Gupta A, Sankar V, Park JS, Jure-Kunkel M, Novotny J, Cogswell J, Zhang X, Phillips T, Simmons P, Simon J. Association of tumor PD-L1 expression and immune biomarkers with clinical activity in patients with non-small cell lung cancer treated with nivolumab. J Thorac Oncol. 2013;8 (suppl:abstract P2.11-035.
-
- Cappuzzo F, Varella-Garcia M, Shigematsu H, Domenichini I, Bartolini S, Ceresoli GL, Rossi E, Ludovini V, Gregorc V, Toschi L, Franklin WA, Crino L, Gazdar AF, Bunn PA, Jr, Hirsch FR. Increased HER2 gene copy number is associated with response to gefitinib therapy in epidermal growth factor receptor-positive non-small-cell lung cancer patients. J Clin Oncol. 2005;23:5007–5018. - PubMed
-
- Cappuzzo F, Hirsch FR, Rossi E, Bartolini S, Ceresoli GL, Bemis L, Haney J, Witta S, Danenberg K, Domenichini I, Ludovini V, Magrini E, Gregorc V, Doglioni C, Sidoni A, Tonato M, Franklin WA, Crino L, Bunn PA, Jr, Varella-Garcia M. Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. J Natl Cancer Inst. 2005;97:643–655. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous